PepGen continues trials for DMD treatment, addresses safety concerns
BOSTON - PepGen Inc. (NASDAQ: PEPG), a biotechnology firm focused on oligonucleotide therapies for severe neuromuscular and neurological diseases, is progressing with its CONNECT clinical program for ...
Dyne Therapeutics: Moving Forward On 2 Key Fronts
Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. Learn more ...
Avidity Biosciences chief scientific officer sells shares worth $162,191
The shares were sold at a weighted average price, with prices ranging from $28.59 to $28.63 per share, amounting to a total ...
Muscular Dystrophy News6d
FDA awards fast track designation to DM1 treatment DYNE-101
The FDA has granted fast track designation to DYNE-101, a therapy for myotonic dystrophy type 1 (DM1) now in testing in a ...